Voluntary recall of a single serial of IMRAB® 3TF, 1 mL rabies vaccine
Voluntary recall of single serial of rabies vaccine | Boehringer Ingelheim US
February 13, 2026 - Boehringer Ingelheim has initiated a voluntary recall of a single serial of IMRAB® 3TF, 1 mL rabies vaccine after a limited number of vials in this serial were found to contain sterile water instead of vaccine. While very few affected vials (containing sterile water) have been identified to date, out of an abundance of caution, we acted decisively and quickly to recall this impacted serial. Veterinarians and clinics that received vaccine from this serial have been notified directly and will be in contact with pet owners whose pet was vaccinated with the recalled serial. We are also recommending revaccination for any pet that received a vaccine from this serial to avoid gaps in protection, maintain compliance with local rabies regulations, and protect public health.
This voluntary recall is being conducted with the knowledge and input of the U.S. Department of Agriculture, Center for Veterinary Biologics, and we have also been in communication with veterinary officials in states impacted by this recall.
The single impacted serial represents approximately 2.5% of the total IMRAB® doses sold annually in the United States in 2025. While the impact to the total U.S. population of veterinary clinics and pets is limited, we recognize that it is a significant impact to those veterinarians, clinics, and pet owners and we are committed to supporting them throughout this process. As a company, Boehringer Ingelheim remains dedicated to the health and well-being of animals and people as well as continuing our history of disease prevention.